No information is available on the clinical use of adagrasib during breastfeeding. Because adagrasib is 98% bound to plasma proteins, the amount in milk is likely to be low. However, because of its potential toxicity in the breastfed infant and its half-life of 23 hours, the manufacturer recommends that breastfeeding be discontinued during adagrasib therapy and for 1 week after the last dose.
关于阿达格拉西布在母乳喂养期间的临床应用尚无可用信息。由于阿达格拉西布与血浆蛋白的结合率为98%，其在乳汁中的含量可能较低。然而，鉴于其对母乳喂养婴儿的潜在毒性以及23小时的半衰期，制造商建议在阿达格拉西布治疗期间及最后一剂后1周内停止母乳喂养。
